Cargando…
Long lasting control of viral rebound with a new drug ABX464 targeting Rev – mediated viral RNA biogenesis
BACKGROUND: Current therapies have succeeded in controlling AIDS pandemic. However, there is a continuing need for new drugs, in particular those acting through new and as yet unexplored mechanisms of action to achieve HIV infection cure. We took advantage of the unique feature of proviral genome to...
Autores principales: | Campos, Noëlie, Myburgh, Renier, Garcel, Aude, Vautrin, Audrey, Lapasset, Laure, Nadal, Erika Schläpfer, Mahuteau-Betzer, Florence, Najman, Romain, Fornarelli, Pauline, Tantale, Katjana, Basyuk, Eugénia, Séveno, Martial, Venables, Julian P, Pau, Bernard, Bertrand, Edouard, Wainberg, Mark A, Speck, Roberto F, Scherrer, Didier, Tazi, Jamal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422473/ https://www.ncbi.nlm.nih.gov/pubmed/25889234 http://dx.doi.org/10.1186/s12977-015-0159-3 |
Ejemplares similares
-
ABX464 (Obefazimod) Upregulates miR-124 to Reduce Proinflammatory Markers in Inflammatory Bowel Diseases
por: Apolit, Cécile, et al.
Publicado: (2022) -
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing
por: Vautrin, Audrey, et al.
Publicado: (2019) -
RNA sequencing analysis of activated macrophages treated with the anti-HIV ABX464 in intestinal inflammation
por: Manchon, Laurent, et al.
Publicado: (2017) -
The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages
por: Chebli, Karim, et al.
Publicado: (2017) -
Safety, tolerability and impact on viral reservoirs of the addition to antiretroviral therapy of ABX464, an investigational antiviral drug, in individuals living with HIV-1: a Phase IIa randomised controlled study
por: Rutsaert, Sofie, et al.
Publicado: (2019)